Acquisition of BMS Pakistan

RNS Number : 5934K

GlaxoSmithKline PLC

22 December 2008

 



Issued: Monday 22 December 2008, London UK - LSE Announcement

GSK to acquire BMS Pakistan

GlaxoSmithKline (GSK) announced today that it has entered into a definitive agreement through which GSK will acquire Bristol-Myers Squibb Pakistan (Private) Ltd. (BMSP) and certain associated trademarks for approximately $36.5 million (£24.6 million). 

Commenting on the acquisition Abbas Hussain, President, Emerging Markets, GSK said, "We are continuing to make investments in emerging markets, to grow and diversify GSK's business. This acquisition reinforces our commitment to Pakistan, broadening our product portfolio and helping us to meet the needs of patients."

GSK will acquire a portfolio of over 30 well-established pharmaceutical brands, many of which occupy leading market positions in key therapeutic disease areas in Pakistan. The BMSP product portfolio, which includes antibiotics, vitamins and dermatology products is complementary to GSK's existing portfolio and will also provide new opportunities for GSK in the fast-growing therapeutic areas of cardiovascular and oncology. Total sales of the BMSP product portfolio in 2007 were PKR1.5bn (approximately $19m). 

Completion of the acquisition is expected by early next year.

Notes to editors

This acquisition follows the agreement GSK announced with South African based pharmaceuticals company Aspen in July 2008, which significantly extended GSK's pharmaceuticals portfolio in emerging markets, and the acquisition of the Egyptian mature products business of Bristol-Myers Squibb, announced in October 2008.

Emerging markets are forecast to account for 40% of growth in the worldwide pharmaceutical market by 2020. 

GSK has been operating in Pakistan since 1948 and is a market leader in the local industry in value, volume and prescription shares.  Pakistan is the sixth most populous country in the world with a population of approximately 161 million. The pharmaceutical business in Pakistan is valued at $1.2 billion (£0.8 billion) and grew at a CAGR of 12% over the last 5 years (Source: IMS). 

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com

S M Bicknell

Company Secretary

22 December 2008   

Enquiries:
UK Media enquiries:	Philip Thomson	[phone]
	Alice Hunt	[phone]
	Stephen Rea	[phone]
US Media enquiries:	Nancy Pekarek	[phone]
	Mary Anne Rhyne	[phone]
	Sarah Alspach	[phone]
European Analyst/Investor enquiries:	David Mawdsley	[phone]
	Sally Ferguson	[phone]
	Gary Davies	[phone]
US Analyst/ Investor enquiries:	Tom Curry	[phone]
	Jen Hill	[phone]

Cautionary statement regarding forward-looking statements Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company' s Annual Report on Form 20-F for 2007.

 

END

 

 

ACQBBBDDGUDGGID